Synapse - Works

Results (115372)

Teclistamab population pharmacokinetics and exposure-response relationship support 1.5 Mg/Kg dose regimen in relapsed/refractory multiple myeloma

Meeting Abstract

Miao, X.; Wu, L. S.; Wang Lin, S. X.; Xu, Y.; Chen, Y.; Iwaki, Y.; Kobos, R.; Stephenson, T.; Kemmerer, K.; Uhlar, C. M.; more...
Blood (2022)

Fulltext@MSK | Save

Initiating first-line (1L) Ibrutinib (Ibr) in patients (pts) with chronic lymphocytic leukemia (CLL) improves overall survival (OS) outcomes to rates approximating an age-matched population of ≥65 years

Meeting Abstract

Ghia, P.; Owen, C.; Barrientos, J. C.; Barr, P. M.; Mato, A. R.; Shi, C. X.; Szoke, A.; Abbazio, C.; Krigsfeld, G. S.; Burger, J. A.
Blood (2022)

Fulltext@MSK | Save

Comparing acalabrutinib and ibrutinib in the real world: A study of 2,509 patients with chronic lymphocytic leukemia

Meeting Abstract

Roeker, L. E.; DerSarkissian, M.; Ryan, K. J.; Chen, Y.; Wahlstrom, S. K.; Hakre, S.; Yu, L.; Guo, H.; Mato, A. R.
Blood (2022)

Fulltext@MSK | Save

Stem cell mobilization characteristics for transplant eligible patients with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib, lenalidomide, dexamethasone, and daratumumab (KRd-Dara)

Meeting Abstract

Bhutani, M.; Robinson, M.; Atrash, S.; Watts, N.; Paul, B.; Chhabra, S.; Korde, N.; Begic, X.; Foureau, D. M.; Chung, D. J.; more...
Blood (2022)

Fulltext@MSK | Save

A phase 2a/2b multicenter study of AG-946 in patients with anemia due to lower-risk myelodysplastic syndromes

Meeting Abstract

Al-Samkari, H.; Fenaux, P.; Sekeres, M. A.; Stein, E.; Sallman, D. A.; Brunner, A. M.; Gurov, X. D.; Yin, O.; Frisbie, M.; Xiao, J.; more...
Blood (2022)

Fulltext@MSK | Save

Mutational profile of children with myeloproliferative neoplasms

Meeting Abstract

Rutherford, K.; Farnoud, N.; Krishnan, A.; Rampal, R. K.; Levine, R. L.; Kucine, N.
Blood (2022)

Fulltext@MSK | Save

Safety and tolerability of pirtobrutinib monotherapy in patients with B-cell malignancies who were previously intolerant to a covalent BTK inhibitor: Results from the phase 1/2 BRUIN study

Meeting Abstract

Shah, N. N.; Wang, M. L.; Brown, J. R.; Patel, K.; Woyach, J. A.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; Alencar, A. J.; more...
Blood (2022)

Fulltext@MSK | Save

MYLOX-1: An open-label, phase IIa study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral LOXL2 inhibitor, GB2064, in myelofibrosis

Meeting Abstract

Verstovsek, S.; Mascarenhas, J.; Rampal, R. K.; Cilloni, D.; Harrison, C.; Jacoby, B.; Slack, R. J.; Aslanis, V.; Singh, B.; Lindmark, B.
Blood (2022)

Fulltext@MSK | Save

Long-term molecular testing and clinical response of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: 5-year follow-up from SIMPLICITY, a prospective, observational study

Meeting Abstract

Cortes, J. E.; Goldberg, S. L.; Paquette, R.; Williams, L. A.; Hehlmann, R.; Michallet, M.; Gambacorti-Passerini, C.; Tang, D. R.; DeGutis, I. S.; McBride, A.; more...
Blood (2022)

Fulltext@MSK | Save

Asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase (CML-CP)-H. Jean Khoury Cure CML Consortium study

Meeting Abstract

Atallah, E. L.; Visotcky, A.; Flynn, K. E.; Zhang, M. J.; Radich, J. P.; Yang, J.; Oehler, V. G.; Tantravahi, S. K.; Smith, B. D. D.; Ibarz, J. P.; more...
Blood (2022)

Fulltext@MSK | Save